EPG Online Twitter
EPG Online Blog
Disease Knowledge
Drug Updates
- Fostair 100/6 inhalation solution
- Epanutin capsules 25, 50 and 100mg
- Eprex 2000, 4000 and 10000 IU/ml solution for injection in pre-filled syringe
- FemSeven Conti
- Epanutin 300mg hard capsules
- Bedranol 80mg SR Capsules
- Bedranol 160mg SR Capsules
- Betim 10mg Tablets
- Carbo-Dome Cream
- Bisoprolol 2.5mg/5mg/10mg film coated tablet
- Phenergan Injection
- Rivotril 0.5 mg and 2 mgTablets
- Rivotril Ampoules
- RELPAX 20mg and 40mg Film-Coated Tablets
- Witch Doctor ® 81.5%w/w Gel
- Levetiracetam Actavis 1,000 mg film-coated tablets
- Levetiracetam Actavis 250 mg film-coated tablets
- Levetiracetam Actavis 500 mg film-coated tablets
- Levetiracetam Actavis 750 mg film-coated tablets
- Lidocaine Hydrochloride Injection BP 1% w/v plastic ampoules
- Lidocaine Hydrochloride Injection BP 2.0% w/v
- Omeprazole 10mg Capsules
- Omeprazole 20mg Capsules
- Panadol Extra Advance 500 mg/65 mg Tablets
- Allopurinol Tablets BP 300mg
- Allopurinol Tablets BP 100mg
- Anadin Ultra Double Strength 400mg Capsules/Anadin LiquiFast 400mg Capsules
- Calcipotriol Scalp Solution
- Bupivacaine Hydrochloride Injection BP 0.5% w/v.
- Lescol (fluvastatin* sodium) 20 mg and 40 mg capsules
- Meropenem 1 g Powder for Solution for Injection or Infusion
- VALTREX Tablets 250mg
- Vesicare 5mg & 10mg film-coated tablets
- Zomig 5mg Nasal Spray
- Water for Injections
- Tizanidine 2mg Tablets
- NovoRapid 100 U/ml in a vial, NovoRapid Penfill 100 U/ml, NovoRapid FlexPen 100 U/ml, NovoRapid FlexTouch 100 U/ml
- Orfadin 10 mg hard capsules
- Orfadin 2 mg hard capsules
- Natecal D3 Chewable Tablets
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
Low molecular weight heparins (LMWHs).
Reviparin sodium
Solution for subcutaneous injection in prefilled syringes.
Injection, reviparin sodium equivalent to 1,432 units of anti-Factor Xa activity per 0.25mL.
Prevention of thrombosis and thromboembolism.
0.25mL once daily by subcutaneous injection. First injection should be given two hours before surgery. Continue treatment until patient is fully mobile; usual duration of therapy, seven days.
Not recommended.
Must not be used in central nervous system surgery, lumbar puncture, spinal anaesthesia and peridural anaesthesia. Known hypersensitivity to reviparin sodium and/or heparin hypersensitivity, including allergic thrombocytopenias. allergic thrombocytopenias. Conditions associated with an elevated bleeding risk, such as: haemorrhagic diathesis; coagulation factor deficit; severe liver, kidney or pancreatic disease; severe thrombocytopenia. Disease suggestive of vascular lesion, such as: active peptic ulcer; hypertension; haemorrhagic stroke; cerebral artery aneurysm; retinopathies; vitreous body haemorrhage; endocarditis lenta. Imminent abortion. Suspected malignancy associated with elevated bleeding risk. Kidney stones. Chronic alcoholism. Pregnancy.
Not for intramuscular administration. Avoid intramuscular injection of other medicines during treatment. Switching between different brands of LMWH during treatment not recommended. Risk of hyperkalaemia; measure plasma potassium before starting treatment then monitor regularly. Lactation.
Drugs affecting blood coagulation (eg, aspirin, coumarin derivatives, dipyridamole, dextrans, cephalosporins, high- dose penicillin). NSAIDs (eg, phenylbutazone, indomethacin), sulphinpyrazone. Nitroglycerin infusion. Further interactions, for example, with antihistamines, cardiac glycosides, tetracyclines, should not be precluded. Caution with drugs that raise serum potassium.
Local injection site reactions. Dose dependent: raised incidence of bleeding, particularly from the skin, mucous membranes, wounds, gastrointestinal tract and urogenital tract. Occasionally, mild thrombocytopenia. Rarely, severe thrombocytopenia, hypersensitivity reactions, anaphylactic reactions, alopecia, hyperkalaemia. Osteoporosis cannot be excluded with long-term treatment.
ICN
(POM)
30 June 2009
- ACTILYSE
- AGGRASTAT
- ALPHAPARIN
- ANGETTES 75
- ASASANTIN RETARD
- Aspirin (MI)
- CANUSAL
- CAPRIN (MI)
- CLIVARINE
- Clopidogrel 75 mg Film-coated Tablets
- Dipyridamole
- DISPRIN CV
- FLOLAN
- Fragmin - Treatment of VTE
- Heparin calcium 25,000 I.U./ml Solution for injection or concentrate for solution for infusion
- HEPSAL
- INTEGRILIN
- KABIKINASE





